The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

In a candid conversation, tennis legend Serena Williams sheds light on her experience with GLP-1 medication, revealing her journey towards body positivity and health. As a mother of two and a 23-time ...

The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...

Viking's VK2735 shows promise in obesity treatment but faces tolerability concerns. Discover market impact, buyout potential, ...

Serena Williams, one of the most successful athletes of all time, has spoken out about using weight loss drugs - she says, to lift the "stigma" around using such medication. Will her outspoken ...

Serena Williams is already feeling the pressure as the Sister of the Bride. During an appearance on the “ Today ” show ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...